Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 18, Issue 12, pp. 2421-2432
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 8, 2019
- Revision received June 26, 2019
- Accepted September 10, 2019
- Published first September 16, 2019.
Article Versions
- Previous version (September 16, 2019 - 06:58).
- Previous version (November 21, 2019 - 06:57).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Tianshu Feng,
- Javad Golji,
- Ailing Li,
- Xiamei Zhang,
- David A. Ruddy,
- Daniel P. Rakiec,
- Felipe C. Geyer,
- Jane Gu,
- Hui Gao,
- Juliet A. Williams,
- Darrin D. Stuart*, and
- Matthew J. Meyer*
- Oncology Drug Discovery, Novartis Institutes for BioMedical Research (NIBR), Cambridge, Massachusetts.
- ↵*Corresponding Authors:
Matthew J. Meyer, Bristol-Myers Squibb, 100 Binney Street, Cambridge, MA 02142. Phone: 617-494-7466; E-mail: matthew.meyer{at}bms.com; and Darrin D. Stuart, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139. Phone: 617-871-5311; E-mail: darrin.stuart{at}novartis.com
December 2019
Volume 18, Issue 12
Volume 18, Issue 12
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Jump to section
Advertisement